Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias

Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Christopher D., Bonkovsky, Herbert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465260/
https://www.ncbi.nlm.nih.gov/pubmed/36105850
http://dx.doi.org/10.1016/j.ymgmr.2022.100915
Descripción
Sumario:Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that elagolix is porphyrogenic; thus, elagolix should be avoided or used with caution in patients with the AHPs.

Ejemplares similares